CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23
Nucleic Acids Research · 2024-04-12 · 52 (6) · 2761-2775
DOI: 10.1093/nar/gkae167 ↗At a glance
Journal article in Nucleic Acids Research, published online on 2024-03-13. Written by Sabine Grüschow and 6 co-authors. Institution: Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, Fife KY16 9ST, UK. Major MEDLINE topics: CRISPR-Associated Proteins, Bacterial Proteins, Vibrio cholerae. Cited 32 times so far (Crossref); 80 references. The full text is freely available (open access, CC BY 4.0). Funded by: Biotechnology and Biological Sciences Research Council, European Research Council Advanced, Engineering and Physical Sciences Research Council.
Abstract (original language)
CRISPR-Cas provides adaptive immunity in prokaryotes. Type III CRISPR systems detect invading RNA and activate the catalytic Cas10 subunit, which generates a range of nucleotide second messengers to signal infection. These molecules bind and activate a diverse range of effector proteins that provide immunity by degrading viral components and/or by disturbing key aspects of cellular metabolism to slow down viral replication. Here, we focus on the uncharacterised effector Csx23, which is widespread in Vibrio cholerae. Csx23 provides immunity against plasmids and phage when expressed in Escherichia coli along with its cognate type III CRISPR system. The Csx23 protein localises in the membrane using an N-terminal transmembrane α-helical domain and has a cytoplasmic C-terminal domain that binds cyclic tetra-adenylate (cA4), activating its defence function. Structural studies reveal a tetrameric structure with a novel fold that binds cA4 specifically. Using pulse EPR, we demonstrate that cA4 binding to the cytoplasmic domain of Csx23 results in a major perturbation of the transmembrane domain, consistent with the opening of a pore and/or disruption of membrane integrity. This work reveals a new class of cyclic nucleotide binding protein and provides key mechanistic detail on a membrane-associated CRISPR effector.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, Fife KY16 9ST, UK.
- Biomedical Sciences Research Complex, School of Chemistry, Centre of Magnetic Resonance, University of St Andrews, St Andrews, Fife, KY16 9ST, UK.
ORCID profiles: Tracey M Gloster, Malcolm F White
Funding
- Biotechnology and Biological Sciences Research Council
- European Research Council Advanced
- Engineering and Physical Sciences Research Council
- BBSRC
- University of St Andrews
Cite
APA
Grüschow, S., McQuarrie, S., Ackermann, K., McMahon, S., Bode, B. E., Gloster, T. M., & White, M. F. (2024). CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23. Nucleic Acids Research, 52(6), 2761-2775. https://doi.org/10.1093/nar/gkae167
Vancouver
Grüschow S, McQuarrie S, Ackermann K, McMahon S, Bode BE, Gloster TM, et al. CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23. Nucleic Acids Research. 2024;52(6):2761-2775. doi:10.1093/nar/gkae167
BibTeX
@article{Grschow2024,
author = {Grüschow, Sabine and McQuarrie, Stuart and Ackermann, Katrin and McMahon, Stephen and Bode, Bela E and Gloster, Tracey M and White, Malcolm F},
title = {CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23},
journal = {Nucleic Acids Research},
year = {2024},
volume = {52},
number = {6},
pages = {2761--2775},
doi = {10.1093/nar/gkae167}
}
EUVIMED